Wednesday, 4 February 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 04 February 2026
News

Aussies drive brain cancer drug

Posted 4 February 2026 AM

Australia is spearheading the world-first clinical trial of Providence Therapeutics’ personalised cancer vaccine for children and adolescents with some of the most aggressive and treatment-resistant brain cancers.

The Canadian mRNA medicines platform company has partnered with the University of Queensland and the South Australian Health and Medical Research Institute (SAHMRI), which will co-lead the project after receiving $2.578 million in funding from the Australian Government.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (16)

Access & Reimbursement (1)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (5)

Other (20)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.